ContentsSynopsisCodesLook ForDiagnostic PearlsDifferential Diagnosis & PitfallsBest TestsManagement PearlsTherapyDrug Reaction DataReferencesView all Images (4)
Female breast cancer
Print
Other Resources UpToDate PubMed

Female breast cancer

Print Images (4)
Contributors: Amirah Khan MD, Paritosh Prasad MD
Other Resources UpToDate PubMed

Synopsis

Breast cancer is the leading cause of cancer-associated mortality in women worldwide and is the most common cause of cancer in the United States and the second most common cancer worldwide (after lung cancer). The incidence of female breast cancer is about 124.7 per 100 000 patients. Male breast cancer is much less prevalent. Breast cancer is rarely diagnosed in childhood or adolescence, and the incidence increases with age. Since the average lifetime risk of the diagnosis of breast cancer is around 12.4%, screening is recommended for average-risk individuals beginning at age 50. In average-risk individuals between ages 40 and 50, screening may be pursued after discussion with the primary care provider, weighing the benefits and risks. Screening is done with mammography.

Risk factors associated with breast cancer include genetic predisposition (BRCA1, BRCA2, PTEN, TP53 mutations), increasing age, Northern European descent, obesity in postmenopausal women, family history of breast / ovarian / peritoneal cancer, and personal history of ovarian, breast, or peritoneal cancer.

In countries with established screening programs, the majority of breast cancers present due to abnormal mammogram findings. Despite this, almost 1 in 6 women who are diagnosed with breast cancer present with a breast mass not detected by mammogram, and a little under 1 in 3 will present with a mass that developed in the interval between mammograms.

Breast cancer typically presents as a painless, immobile breast lump or abnormality found on mammography. In more advanced cases, it can present with bloody nipple discharge, axillary lymphadenopathy, thickening and erythema of the skin (peau d'orange appearance), and metastatic disease commonly found in bone, liver, and lungs. Ductal carcinoma in situ (DCIS) is considered a precursor lesion and is confined to breast ducts and lobules.

The diagnosis of breast cancer is made based on malignant-appearing cells found on biopsy. The treatment of breast cancer varies according to stage of disease as well as histologic and genetic subtype of the malignancy. Common histologic subtypes include infiltrating ductal carcinoma, infiltrating lobular carcinoma, and mixed ductal / lobular carcinoma. Tumor expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) is used to predict outcomes and guide treatment.

For more information on BRCA1 gene susceptibility, see OMIM.

For more information on BRCA2 gene susceptibility, see OMIM.

Related topic: Cutaneous breast cancer

Codes

ICD10CM:
C50.919 – Malignant neoplasm of unspecified site of unspecified female breast

SNOMEDCT:
254837009 – Malignant tumor of breast

Look For

Subscription Required

Diagnostic Pearls

Subscription Required

Differential Diagnosis & Pitfalls

Best Tests

Subscription Required

Management Pearls

Subscription Required

Therapy

Subscription Required

Drug Reaction Data

Below is a list of drugs with literature evidence indicating an adverse association with this diagnosis. The list is continually updated through ongoing research and new medication approvals. Click on Citations to sort by number of citations or click on Medication to sort the medications alphabetically.

Subscription Required

References

Subscription Required

Last Reviewed: 04/18/2019
Last Updated: 05/22/2019
Copyright © 2019 VisualDx®. All rights reserved.
Female breast cancer
Print 4 Images
View all Images (4)
(with subscription)
Female breast cancer : Nipple discharge, Breast lump
Copyright © 2019 VisualDx®. All rights reserved.